开云·kaiyun(体育)官方网站-登录入口

BioHub financing case

Biohub FA services: Biohub: your professional financial advisor focused exclusively in Healthcare sector
Experienced in long-term tracking of healthcare market and investment trends, we provide financing advisory solutions to early incubation projects and emerging growth healthcare companies. We work with you on the need identification, strategic Planning, Business Assessment and Business Plan adjustment. Leveraging our long-standing relationships with institutional and private capital sources, we can connect you with the right capital and accompany you through the whole negotiation and transaction process. In recent three years we have completed more than 10 transactions and have raised more than 500Million+ RMB.

Series A round:tens of millions RMB

Vickor Medtech

Wuhan, China

Financing amount: tens of millions

Financing round: Round A

George Li Board Director

Vickor Medtech

Vickor Medtech focuses on innovative minimally invasive interventional devices for structural heart disease and heart failure. The current products include atrial shunts for heart failure, PFO for unknown stroke, and regurgitation valves. The atrial shunt product has completed FIM study and is conducting registrational clinical trials in multiple centers. PFO for the treatment of unexplained stroke has completed the registration of all clinical patients.
MORE：http://www.vickor.com.cn/
Series A round:tens of millions RMB

jasmine

Chengdu, China

Financing amount: tens of millions

Financing round: round a

负责人：李喆

jasmine

Jisi Mingzhi eye movement detector: the Jisi Mingzhi project, led by domestic university professors, made progress in the research on the association between eye movement detection and analysis and Alzheimer's disease in 2015, obtained good feedback on its trial in many clinical hospitals, published variable and high-quality literature, and obtained an independent patent in 2018.
MORE：
Series C: Several hundred millions RMB

NanoVision Tehcnologies

NanoVision Tehcnologies

MORE：
Series C: Several hundred millions RMB

Langcare Medtech

Langcare Medtech

MORE：
Series A: tens of millions RMB

Series B: Several hundred millions RMB
Nano Ablation Biotech

Nano Ablation Biotech

Hangzhou Nano Ablation Biotech is committed to building an innovative ablation platform based on bioelectric technology. The company has developed an internationally leading next-generation pulse ablation technology, nanosecond wave ablation, which can achieve local accurate ablation, break through into forbidden area that traditional ablation technology can not, and is expected to create strong immune response which can address traditional tumor surgical problems of tumor recurrence and metastasis. At present, Hangzhou Nano Ablation Biotech is about to complete the world's first registered clinical trial for nanosecond wave tumor ablation. The company has a pipeline of products targeting liver cancer, pancreatic cancer, and cardiac ablation.
MORE：
Series A: Several hundred millions RMB

MobiDrop Biotech

China's zhejiang province

Financing amount: hundreds of millions of yuan

Financing round: Round A

George Li Board Director

MobiDrop Biotech

MobiDrop is committed to empowering scientific research and precision medicine with innovative microfluidics and single-cell sequencing technologies. At present, the company develops key technologies such as microfluidics, sequencing, biochemistry, hardware development, and bioinformatics. MobiDrop has launched an innovative single-cell sequencing technology platform and a digital PCR technology platform.
MORE：https://www.mobidrop.com/